July 10, 2018 Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager National Center for Advancing Translational Sciences National Institutes of Health Email firstname.lastname@example.org Re: Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer to Apexx… Continue Reading
On July 9, 2018, KEI asked the NIH to extend the deadline for comments described on the Federal Register notice 83 FR 30448 until information about the enrollment and costs of NIH-funded clinical trials involving mesothelin expressing cancers, and trials… Continue Reading
On Friday May 11, 2018, the Department of Health and Human Services (DHHS) held its annual listening session in advance of the upcoming World Health Assembly. Comments were limited to 2 minutes, with no time set aside for a question… Continue Reading
In November 2017, the World Health Organization (WHO) published a report charting a path forward for the expansion of WHO’s work on the transparency of R&D costs and medicines prices while rekindling the prospects for WHO to assume the mantle of… Continue Reading
- After KEI filed a complaint with the NIH, Cold Spring Harbor Laboratory (CSHL) corrected a failure to disclose funding of at least 7 patented inventions, including one patent for the drug Sprinraza.
- Since 2012, when federal funding was relevant to an invention, CSHL failed to make a disclosure on a filed patent more than half the time.
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) The attached file (copy here) is the KEI questions and initial comments on the Prospective Grant of an Exclusive Patent License: Apparatus for Microarray Binding Sensors Having… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Attached are the August 8, 2017 KEI comments regarding the prospective grant of an exclusive patent license by the NIH to Salubris Biotherapuetics for the development of… Continue Reading
On August 8, 2017, Knowledge Ecology International (KEI) submitted comments on the proposed grant of an exclusive license from the National Institutes of Health (NIH) and Department of Health and Human Services (HHS) to Salubris Biotherapuetics, Inc, a corporation headquartered in Guangdong, China, for an important new technology that could be used Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On July 10, 2017, the NIH issued a notice on “Prospective Grant of Exclusive Patent License: Composition and Methods for Delivering Inhibitory Oligonucleotides for the Treatment of… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) In 2016, the NIH signed a CRADA with NantBioScience, a company lead by Patrick Soon-Shiong, MD. to develop “Further Develop Recombinant NK Cells and Monoclonal Antibodies as… Continue Reading